Poseida Therapeutics, Inc. (NASDAQ:PSTX) Chairman Mark J. Gergen Sells 30,000 Shares of Stock

Poseida Therapeutics, Inc. (NASDAQ:PSTX) Chairman Mark J. Gergen sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $9.27, for a total value of $278,100.00. Following the completion of the sale, the chairman now directly owns 651,291 shares of the company’s stock, valued at $6,037,467.57. The trade was a 4.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Poseida Therapeutics Stock Down 0.5 %

Shares of PSTX opened at $9.33 on Thursday. The firm has a fifty day moving average price of $3.02 and a 200-day moving average price of $3.01. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $909.35 million, a P/E ratio of -14.81 and a beta of 0.54. Poseida Therapeutics, Inc. has a 12-month low of $1.87 and a 12-month high of $9.42.

Institutional Investors Weigh In On Poseida Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Bayesian Capital Management LP purchased a new position in shares of Poseida Therapeutics during the first quarter worth approximately $33,000. Marshall Wace LLP purchased a new position in Poseida Therapeutics during the 2nd quarter worth $31,000. Rothschild Investment LLC bought a new stake in Poseida Therapeutics during the 2nd quarter valued at $35,000. Principal Financial Group Inc. bought a new stake in Poseida Therapeutics during the 2nd quarter valued at $35,000. Finally, Virtu Financial LLC purchased a new stake in shares of Poseida Therapeutics in the 3rd quarter worth $37,000. 46.87% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. BTIG Research restated a “neutral” rating on shares of Poseida Therapeutics in a research report on Tuesday. HC Wainwright restated a “neutral” rating and issued a $9.00 target price (down previously from $20.00) on shares of Poseida Therapeutics in a report on Tuesday. William Blair reiterated a “market perform” rating on shares of Poseida Therapeutics in a report on Tuesday. Finally, Cantor Fitzgerald lowered shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Four analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $9.50.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.